Procaps (US:PROC) Globenewswire·2025-01-03 21:15Core Points - Procaps Group, a leading integrated LatAm healthcare and pharmaceutical services company, received a notice from Nasdaq regarding an additional filing delinquency related to its interim financial statements for the period ended June 30, 2024 [1][2] - The interim financial statements were due by December 31, 2024, but were not filed due to delays in the filing of the Company’s Form 20-F for the fiscal year ended December 31, 2023, violating Nasdaq Listing Rule 5250(c)(2) [2] - The Nasdaq Hearings Panel will consider this delinquency in its deliberations regarding Procaps' request for continued listing on Nasdaq, and the Company plans to respond and present its compliance plan at the upcoming hearing [3] Company Overview - Procaps Group is a prominent developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies, operating in over 50 countries across all five continents [4] - The Company has a direct presence in 13 countries in the Americas and employs nearly 5,000 individuals under a sustainable model [4] - Procaps develops, manufactures, and markets a range of products including over-the-counter (OTC) pharmaceutical products, prescription drugs (Rx), nutritional supplements, and high-potency clinical solutions [4]